The premise of this combination is that the ADCs will localize around HER2-positive tumor cells; once bound, the free Fc-region of the ADC can interact with macrophages and dendritic cells, effectively delivering the TLR agonist to induce direct macrophage killing of the malignant cells and promote tumor-specific lymphocyte response [259]. The gene discussed is ERBB2; the disease is neoplasm.